Reported Earlier, Renalytix Fights Nasdaq Delisting with Strategic Plan, Trading Temporarily Safe
Portfolio Pulse from Benzinga Newsdesk
Renalytix plc (NASDAQ:RNLX) has submitted a hearing request to the Nasdaq Hearings Panel to stay the suspension of its securities. The company plans to present a strategic plan to regain compliance with Nasdaq listing requirements. The outcome is uncertain, and delisting could impact the stock price and capital-raising ability.
June 28, 2024 | 7:07 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Renalytix plc has submitted a hearing request to the Nasdaq Hearings Panel to stay the suspension of its securities. The company aims to present a strategic plan to regain compliance with Nasdaq listing requirements. The outcome is uncertain, and delisting could impact the stock price and capital-raising ability.
The company's stock will continue trading on Nasdaq pending the Panel's decision. The strategic plan aims to regain compliance, but the outcome is uncertain. If delisted, the stock price could suffer, and capital-raising could be impaired.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100